胰高血糖素样肽1受体激动剂对代谢相关脂肪性肝病作用机制的研究进展  

Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease

作　　者：李娜[1,2] 刘佳 王广[1] 谢国敏[3] 曲爱娟 李红梅[2] LI Na;LIU Jia;WANG Guang;XIE Guomin;QU Aijuan;LI Hongmei(Department of Endocrinology,Beijing Chaoyang Hospital Affiliated to Capital Medical University,Beijing 100020,C hina;Department of Endocrinology,the First Affiliated Hospital of Tsinghua University,Beijing 100016,China;Department of Physiology and Pathophysiology,School of Basic Medical Sciences&Key Laboratory of Remodeling-Related Cardiovascular Diseases,Ministry of Education,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京朝阳医院内分泌科,北京市100020 [2]清华大学第一附属医院内分泌科,北京市100016 [3]首都医科大学基础医学院生理学与病理生理学系,重塑相关心血管疾病教育部重点实验室,北京市100069

出　　处：《中国动脉硬化杂志》2021年第5期446-450,共5页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金面上项目(81770792);北京市自然科学基金B类重点项目(KZ201810025038)。

摘　　要：非酒精性脂肪性肝病(NAFLD)(现已更名为代谢相关脂肪性肝病)是一种以肝实质内脂质过度沉积为特征,常与中心性肥胖、2型糖尿病、胰岛素抵抗、代谢综合征等疾病合并存在,被认为是代谢综合征的肝脏表现。非酒精性脂肪性肝炎(NASH)是一种可能导致肝硬化、肝细胞癌的进行性肝病。目前尚无批准用于治疗NAFLD/NASH的药物。近期研究表明胰高血糖素样肽1(GLP-1)受体激动剂作为降糖药,不仅通过肠促胰素作用改善代谢关键参数间接逆转NAFLD的进展,还直接影响肝细胞脂质代谢、炎症及氧化应激。文章对GLP-1受体激动剂在NAFLD/NASH中的作用及潜在机制进行综述。Nonalcoholic fatty liver disease(NAFLD)is characterized by excessive lipid deposition within the liver parenchyma,and is usually accompanied with obesity,insulin resistance,type 2 diabetes(T2DM),insulin resistance,metabolic syndrome.Recently,NAFLD has been officially renamed metabolic associated fatty liver disease(MAFLD).Nonalcoholic steatohepatitis(NASH)is a progressive liver disease that can lead to cirrhosis,hepatocellular carcinoma.Currently there are no approved drugs available for NAFLD/NASH treatment.Glucagon-like peptide-1(GLP-1)receptor agonist not only reverses the progression of NAFLD indirectly through an incretin effect that improves key metabolic parameters involved in NAFLD,but also has a direct effect on lipid metabolism,inflammation and oxidative stress of hepatocytes.Herein,this study reviews the effects and potential mechanisms of GLP-1 receptor agonists on nonalcoholic fatty liver disease.

关 键 词：代谢相关脂肪性肝病 胰高血糖素样肽1受体激动剂 脂质代谢 自噬 炎症 氧化应激 

分 类 号：R589.2[医药卫生—内分泌]